PULM | tickerfilter.com

Fundamental analysis

19%

Profitability 18%

Dept financing 14%

Liquidity 49%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

10.40%

1 Month

-6.30%

3 Months

-43.69%

6 Months

-55.31%

1 Year

-69.82%

2 Year

20.54%

Key data

Stock price

$2.23

P/E Ratio

0.00

DAY RANGE

$2.05 - $2.25

EPS

-$1.41

52 WEEK RANGE

$1.63 - $9.37

52 WEEK CHANGE

-$72.50

MARKET CAP

8.145 M

YIELD

N/A

SHARES OUTSTANDING

3.652 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-09-2025

BETA

-3.30

PUBLIC FLOAT

AVERAGE 10 VOLUME

$117,002

AVERAGE 30 VOLUME

$50,295

Company detail

CEO: Teofilo Raad
Region: US
Website: pulmatrix.com
Employees: 20
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Pulmatrix, Inc. discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology. Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis, and in patients with cystic fibrosis, is in Phase 1b clinical trials.

PULM - Pulmatrix, Inc.